Jump To Section
Featured Stories
COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
Daiichi Sankyo Enters Europe's Cholesterol Market
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.
Coronavirus Spotlight
COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Recent Tweets from Scrip
COVID-19 Pipeline Tracker
Product candidates in development worldwide to address the 2019-nCoV pandemic, categorized by treatment and prevention. Subscription required.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.
Cash-Rich PureTech Displays Resilience In Troubled Times
PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.
CSL Behring And SAB Explore Polyclonal Antibodies For COVID-19
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.
Purple Patch: US Approval For Cipla's Gx Albuterol, Staggered Supplies Planned
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Arrakis Inks First Partnership In RNA-Targeted Collaboration With Roche
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
US FDA Extends Roche’s Risdiplam Decision Date
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
India Keeps Door Ajar For Hydroxychloroquine Exports, Drug Makers Geared Up
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Research & Development Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Cash-Rich PureTech Displays Resilience In Troubled Times
PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.
IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
'Peoples' Hope' Remdesivir Results Due Soon - What To Look For?
The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.